Parkinson’s Drug Targeting LRRK2 Fails Key Phase 2 Trial, Biogen and Denali Halt Development
Experimental Parkinson’s drug BIIB122 failed to slow disease in trials despite strong biological effects; development stopped.
/ 13 items
#BIIB↓
Biogen Advances Alzheimer’s Drug Diranersen to Phase 3 After It Slashes Tau and Slows Cognitive Decline
Biogen’s diranersen showed robust tau reduction and slowed cognitive decline in early Alzheimer’s Phase 2 trial. Moving to late-stage studies despite missing primary endpoint.
Biogen Buys Apellis for $5.6 Billion: Two New Drugs Supercharge Growth in Rare Diseases & Kidney Care
Biogen is acquiring Apellis for $5.6 billion, adding two approved drugs (Syfovre & Empaveli) for eye disease and rare kidney conditions. Boosts growth and nephrology pipeline.
Biogen Reports $222M R&D Charge Impact on Q4 2025 Earnings
Biogen discloses $222 million charge for research partnerships and licensing agreements, reducing Q4 2025 earnings by $1.26 per share in SEC filing.
HSBC Cuts Biogen Rating as MS Business Weakens
HSBC downgraded Biogen to Reduce, citing weakness in its multiple sclerosis business, margin pressure, and limited near-term earnings growth.
Novo Nordisk Stock Plunges 10% as Ozempic Fails Alzheimer's Trial
Novo Nordisk shares tumbled 10% after Ozempic failed to slow Alzheimer's progression in clinical trials, marking another setback for the struggling Danish drugmaker against rival Eli Lilly.